je.st
news
Tag: controlled
Voltage Controlled Amplifiers: AGC-330 Datasheet
2015-10-14 13:18:56| rfglobalnet Downloads
The AGC-330 is a high-performance TO-3 voltage controlled amplifier with a 5 to 300 MHz operating frequency range. This model also features a typical gain of 22 dB, a high AGC range of 36.0 dB, and a low noise figure of 4.0 dB.
Tags: controlled
voltage
amplifiers
datasheet
Voltage Controlled Amplifiers: AGC230 Datasheet
2015-10-14 13:16:37| rfglobalnet Downloads
The AGC230 is a high-performance TO-8 voltage controlled amplifier with a 20 to 250 MHz operating frequency range. This model also features a typical gain of 46 dB, a high AGC range of 50.0 dB, and a low noise figure of 5.0 dB.
Tags: controlled
voltage
amplifiers
datasheet
Nebraska feedyard keeps flies controlled, people happy
2015-10-13 14:44:40| Beef
While flyswatters are a lot of fun to employ in the battle with bugs, you really want your feedyard cowboys riding pens and filling feed bunks, not hanging around the cowboy shack swatting flies.
Tags: people
happy
controlled
nebraska
Septembers top stories: Remote controlled ferry, Gentings stake in Lloyd Werft
2015-10-11 08:45:00| Ship Technology
Seaspan signs $1bn container agreement with Export-Import Bank of China, EBRD acquires stake in Turkeys Global Ports Holding, and Japans Mitsui tests new horseshoe-shaped windshield on its boxship. Ship-technology.com wraps up the key headlines fro
Tags: top
stories
remote
controlled
Mercks Omarigliptin, an Investigational Once-Weekly DPP-4 Inhibitor, Achieved Similar A1C Reductions to JANUVIA (sitagliptin) in Patients with Type 2 Diabetes Inadequately Controlled on Metformin Monotherapy
2015-09-16 16:16:00| Merck.com - Research & Development News
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that omarigliptin, Mercks investigational once-weekly DPP-4 inhibitor in development for adults with type 2 diabetes, achieved its primary efficacy endpoint in a Phase 3 study. Omarigliptin was found to be non-inferior to Mercks once-daily DPP-4 inhibitor, JANUVIA (sitagliptin), at reducing patients A1C* levels from baseline, with similar A1C reductions achieved in both groups. Language: English Contact: MerckMedia:Pam Eisele, 267-305-3558Michael Close, 310-617-1067Kristen Drake, 917-647-6223orInvestorsJustin Holko, 908-740-1879Teri Loxam, 908-740-1986 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: on
type
similar
controlled
Sites : [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] next »